In a report released on January 14, Evan Seigerman from BMO Capital reiterated a Hold rating on Replimune Group, with a price target of $11.00. The company’s shares closed yesterday at $7.71.

A cutting-edge Cloud Data Specialist seeks the coding talents of a Front End Developer who will be instrumental in building and maintaining data-driven user interfaces for metering data, dashboards, ...

One of the best things about the Android platform is its customization and flexibility. Android lets you use it the way you want to, whether that means changing the launcher, using icon packs, or more ...

Learn the benefits and risks of options and how to start trading options Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Samantha (Sam) Silberstein, CFP®, CSLP®, ...

February 13, 2026 • The ruling temporarily blocks the Trump Administration from cutting $600 million in public health grants that had already been allocated to four Democratic-led states.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...